Preliminary results with administration of recombinant human erythropoietin in sickle cell/beta-thalassemia patients during pregnancy. (otevřeno nové okno)

Bourantas K, Makrydimas G, Georgiou J, Tsiara S, Lolis D.

Zdroj‎: Eur J Haematol 1996;56(5):326-8.

Označení‎: PubMed 8641410

https://www.ncbi.nlm.nih.gov/pubmed/8641410 (otevřeno nové okno)

On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease. (otevřeno nové okno)

el-Hazmi MA, al-Momen A, Kandaswamy S, Huraib S, Harakati M, al-Mohareb F, Warsy AS.

Zdroj‎: Acta Haematol 1995;94(3):128-34.

Označení‎: PubMed 7502628

https://www.ncbi.nlm.nih.gov/pubmed/7502628 (otevřeno nové okno)

Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. (otevřeno nové okno)

Little JA, McGowan VR, Kato GJ, Partovi KS, Feld JJ, Maric I, Martyr S, Taylor JG 6th, Machado RF, Heller T, Castro O, Gladwin MT.

Zdroj‎: Haematologica 2006;91(8):1076-83.

Označení‎: PubMed 16885048

https://www.ncbi.nlm.nih.gov/pubmed/16885048 (otevřeno nové okno)

Use of erythropoietin in a pregnant Jehovah's Witness with sickle-cell disease. (otevřeno nové okno)

Tan TL, Ahmad H, Jhavar R, Patel R, Harrison C, Oteng-Ntim E.

Zdroj‎: J Obstet Gynaecol 2007;27(1):82-3.

Označení‎: PubMed 17365469

Identifikátor digitálního objektu‎: 10.1080/01443610601062739

https://www.ncbi.nlm.nih.gov/pubmed/17365469 (otevřeno nové okno)

The use of barbiturate coma as salvage therapy in a postoperative Jehovah's Witness patient with life-threatening anemia. (otevřeno nové okno)

Wang SW, Badami CD, Deitch EA.

Zdroj‎: Am Surg 2009;75(12):1175-8.

Označení‎: PubMed 19999907

https://www.ncbi.nlm.nih.gov/pubmed/19999907 (otevřeno nové okno)